SpyGlass Pharma unveils 1-year data of drug delivery platform implanted during routine cataract surgery in patients diagnosed with glaucoma

These data will be highlighted in a poster presentation during the American Society of Cataract and Refractive Surgeons (ASCRS) Annual Meeting, held from April 5 to 8 at the Boston Convention and Exhibition Center in Boston.

The company noted in a news release that 1 year after implantation, the enduring IOP reduction remained consistent across all 3 dose strengths, achieving a mean pressure reduction of 44.6% at month 12 compared to pre-operative washed-out baseline levels. All patients sustained more than a 20% IOP reduction from baseline and IOPs of < 18 mm Hg through month 12. Additionally, 100% of patients remain off topical IOP-lowering drops. The SpyGlass platform was well tolerated and there were no adverse events related to the product.

Read more: https://www.ophthalmologytimes.com/view/spyglass-pharma-unveils-1-year-data-of-drug-delivery-platform-implanted-during-routine-cataract-surgery-in-patients-diagnosed-with-glaucoma?ekey=RUtJRDpGQ0FERjM4NC1GNDk3LTQyMzUtOTExQy0yOUNGM0ZEOUJGNkY%3D&utm_campaign=emailname&utm_medium=email&_hsenc=p2ANqtz-8TV7GuF5KwxGB8GUaRC7_vcmrSKbvQXdO5-CziPJHLlXVmgXwQ5-5a8J7GVwxMIffda1bRBXsC0SLJTgfF7yEuwjQ41Q&_hsmi=301108232&utm_source=hs

Source: Ophthalmology Times